Navigation Links
$16.8 million grant awarded to develop platelet recovery treatments
Date:9/30/2009

SEATTLE The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

The collaboration, led by scientists at the Hutchinson Center, will develop molecular- and cell-based therapies for a range of blood diseases, with an initial focus on a life-threatening complication of stem-cell transplantation called thrombocytopenia. The condition, which is sometimes associated with abnormal bleeding, is caused by a delayed recovery of blood-clotting cells called platelets.

The problem is that some stem cell transplant patients, particularly those receiving stem cells from cord blood, often do not produce enough platelets in a timely fashion which puts them at risk for life-threatening bleeding. Platelet production can be delayed by several months in persons who receive a stem cell transplant to treat certain cancers. Transfusions can help, but the number of platelet donors is limited, transfusions carry a risk of blood-borne diseases, and patients who receive multiple transfusions can develop antibodies that destroy the platelets.

According to principal investigator Beverly Torok-Storb, Ph.D., a member of the Hutchinson Center's Clinical Research Division, the goal is to control the process of blood cell production so that all types of blood cells - red cells to carry oxygen, white cells to fight infection and platelets to prevent bleeding - recover together within a few days.

The partner institutions will focus on two complementary strategies to address delayed platelet production. Scientists at the Hutchinson Center and the UW will develop reagents that can be administered to patients to stimulate the differentiation and proliferation of precursor cells into platelets. The Philadelphia group will work to generate "ex vivo," or outside the body, platelets and their precursors from embryonic stem cells for use as cell therapy. The principal investigator in Philadelphia is Mortimer Poncz, M.D., chief of the Division of Hematology at Children's Hospital of Philadelphia.

The Hutchinson Center/UW group will receive a total of $8.2 million during the seven-year grant; the Philadelphia research group will receive $8.6 million.

"This coast-to-coast collaborative effort will take advantage of complementary skills and interests in these two institutions to develop new therapies for all patients needing platelet transfusions," Poncz said.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Johns Hopkins epigenetic center receives $16.8 million NIH grant
2. $16.8 million study will breathe new life into cancer battle
3. Cardinal Health Foundation Invites Health Care Providers to Apply for $1 Million in Grants to Improve Efficiency, Quality of Care
4. Boston University School of Medicines black womens health study receives $9.1 million award
5. Sammons Support for Baylor Health Care System Foundation Tops $20 Million
6. Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant
7. Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment
8. Society of Interventional Radiology Foundation receives $1 million legacy gift
9. The Kingdom of Saudi Arabia Commits $30 Million to Polio Eradication Efforts
10. Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars
11. Kidney advocates launch $10.25 million effort to examine cause of kidney failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to announce ... Wednesday, June 21. , “Introducing our product on QVC is something we all worked hard ... travel pillow to more than 90 million homes in the United States,” said FaceCradle USA ...
(Date:6/20/2017)... ... June 20, 2017 , ... EdChoice ... introduction of school choice can promote economic development in economically distressed urban areas. ... according to the report, contributed to the economic development of the city of ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. ... for leading-edge care, whether or not they have a referral. Dr. Kejriwal offers ... iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... sites. To understand their regulatory principles, the research team developed expressRNA, a web ... RNA motif analyses. This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
(Date:6/1/2017)... Nutriceutical Holdings (NH), parent company of Physician ... KD Pharma Group have decided to join forces through ... Group. KD Pharma Group will become the largest shareholder ... entire company. "We believe we have found ... growing the NH companies by providing us with supply ...
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
Breaking Medicine Technology: